Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/24122

Title: Durable reduction in MRI disease activity with alemtuzumab in treatment-naive patients with active relapsing-remitting multiple sclerosis: 6-year follow-up of the CARE-MS I study
Authors: Arnold, D. L.
Barnett, M.
Comi, G.
Giovannoni, G.
Pelletier, D.
Rovira, A.
Schippling, S.
Van Wijmeersch, Bart
Margolin, D. H.
Thangavelu, K.
Traboulsee, A.
Issue Date: 2016
Citation: MULTIPLE SCLEROSIS JOURNAL, 22(S3), p. 329-329 (Art N° P683)
Notes: [Arnold, D. L.] NeuroRx Res, Montreal, PQ, Canada. [Arnold, D. L.] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada. [Barnett, M.] Univ Sydney, Sydney, NSW, Australia. [Comi, G.] Univ Vita Salute San Raffaele, Milan, Italy. [Giovannoni, G.] Queen Mary Univ London, Barts & London Sch Med, London, England. [Pelletier, D.] Univ Southern Calif, Los Angeles, CA USA. [Rovira, A.] Vall dHebron Univ Hosp, Barcelona, Spain. [Schippling, S.] Univ Zurich Hosp, Neuroimmunol & Multiple Sclerosis Res, Zurich, Switzerland. [Schippling, S.] Univ Zurich, Zurich, Switzerland. [Van Wijmeersch, B.] Univ Hasselt, Hasselt, Belgium. [Margolin, D. H.; Thangavelu, K.] Sanofi Genzyme, Cambridge, MA USA. [Traboulsee, A.] Univ British Columbia, Vancouver, BC, Canada.
URI: http://hdl.handle.net/1942/24122
ISI #: 000383267201422
ISSN: 1352-4585
Category: M
Type: Journal Contribution
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
Published version389.97 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.